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ORIGINAL ARTICLE

Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior
vena cava tumor thrombectomy and concomitant radical
nephrectomy
_______________________________________________
Ross M. Simon 1, Timothy Kim 2, Patrick Espiritu 2, Tony Kurian 1, Wade J. Sexton 2, Julio M. Pow-Sang 2,
Einar Sverrisson 2, Philippe E. Spiess 2
University of South Florida, Department of Urology, Tampa, FL, USA and 2 Department of Genitourinary
Oncology, Moffitt Cancer Center, Tampa, FL, USA
1

ABSTRACT									ARTICLE INFO
______________________________________________________________

______________________

Purpose: To determine if patients with renal cell carcinoma (RCC) with levels III and
IV tumor thrombi are receive any reduction in complication rate utilizing veno-venous
bypass (VVB) over cardiopulmonary bypass (CPB) for high level (III/IV) inferior vena
cava (IVC) tumor thrombectomy and concomitant radical nephrectomy.
Materials and Methods: From May 1990 to August 2011, we reviewed 21 patients that
had been treated for RCC with radical nephrectomy and concomitant IVC thrombectomy employing either CPB (n =16) or VVB (n=5). We retrospectively reviewed our
study population for complication rates and perioperative characteristics.
Results: Our results are reported using the validated Dindo-Clavien Classification system comparing the VVB and CPB cohorts. No significant difference was noted in minor
complication rate (60.0% versus 68.7%, P=1.0), major complication rate (40.0% versus
31.3%, P=1.0), or overall complication rate (60.0% versus 62.5%, P=1.0) comparing
VVB versus CPB. We also demonstrated a trend towards decreased time on bypass
(P=0.09) in the VVB cohort.
Conclusion: The use of VVB over CPB provides no decrease in minor, major, or overall
complication rate. The use of VVB however, can be employed on an individualized basis with final decision on vascular bypass selection left to the discretion of the surgeon
based on specifics of the individual case.
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INTRODUCTION
With the increasing use of cross sectional
imaging over recent years, the incidence of renal
cell carcinoma (RCC) has increased at an average
of 2.5% yearly (1). Although this has led to earlier detection of RCC, 5-10% of patients continue
to present with tumor thrombi formation in the
inferior vena cava (IVC) at the time of diagnosis.
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The presence of thrombi itself portends a poorer
prognosis; however it has been demonstrated that
thrombi level I-IV have equivalent 5-year cancer
specific survival of 32%-68% after surgical intervention (1-5). Even though surgery is warranted in
most patients regardless of the level of thrombus,
an increased perioperative complication rate has
been observed proportional to the proximal extent
of the tumor thrombus. This increase in complica-
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tion rate is in part caused by the frequent need for
vascular bypass to successfully resect bulky level
III and IV IVC tumor thrombi (1-3, 5-9).
In an effort to reduce perioperative complications, liver transplantation techniques that do
not utilize vascular bypass have been successfully
applied for certain level III thrombi. However, there still exists a population of patients that cannot
tolerate the decrease in cardiac return after cross
clamping of the IVC, and require vascular bypass
for successful resection (3, 10-13). Although it is
widely accepted that resection of most level IV
thrombi must be accomplished with cardiopulmonary bypass (CPB), there is controversy over
which type of bypass should be used for level III
thrombi and selected level IV thrombi (1, 6-8,
14, 15). In these patients the use of veno-venous
bypass (VVB) has been utilized in effort to reduce
the risk of perioperative coagulopathy and neurologic and systemic complications associated with
CPB (4, 10-11). Most prior studies examining the
use of VVB have been descriptive in nature except
for a prior peer reviewed study that demonstrated
decreased operative time and bypass time when
compared to CPB (16). The aim of the present study was to validate this prior study’s results at our
own institution while taking an in-depth look at
perioperative complications among RCC patients
with level III or IV IVC tumor thrombi submitted
to such surgery on either VVB or CPB.

dication was present (i.e. allergy to contrast or renal
insufficiency). This was performed to assess the presence of metastases as well as differentiate the level
of the tumor thrombus and carefully clinically stage patients using the American Join Committee on
Cancer (AJCC, 2010) classification (17, 18). Additional tests such as bone scintigraphy were performed
at the discretion of the referring urologist based on
the patient’s clinical presentation. The level of tumor
thrombus was determined using the Mayo Classification Scale of IVC tumor thrombi (1, 18, 19).
A retrospective chart review was performed for demographics, estimated blood loss (EBL),
transfusion of packed red blood cells (PRBC),
bypass pump time, operative time, anesthesia
time, length of hospital stay and overall survival.
Complications were also retrospectively assigned
utilizing the Dindo-Clavien classification system
(20). All patients with IVC tumor thrombi who did
not undergo vascular bypass (n=103) were excluded from the study.
Our surgical technique for resection of level III and IV IVC tumor thrombi has been previously described in the literature and is individualized
based on the clinical characteristics of the patient
and at the discretion of the multidisciplinary surgical team comprised of a cardiothoracic, hepatobiliary, and/or vascular surgeon (8). Most patients
with Level IV thrombi underwent CPB with the
exception of those patients in which the tumor
thrombi could be manually migrated caudally. In
patients with level III tumor thrombi we rely primarily on VVB when vascular bypass is necessary. However, in instances where level III tumor
thrombi cannot be adequately controlled at the
level of the suprahepatic IVC we typically utilize
CPB. In either case the decision to undergo bypass
is determined by our multidisciplinary team based
in part on the height of the thrombus, magnitude
of IVC involvement, bulk of the tumor thrombi,
and the anticipated ability of the patient to tolerate cross-clamping of the IVC. After surgical resection, patients were followed routinely every 3-6
months with history and physical examination,
serological testing, and radiographic imaging of
the chest (chest x-ray, non-contrast CT) and abdomen (CT or MRI with intravenous contrast provided there were no contraindications).

MATERIALS AND METHODS
A retrospective study protocol was approved by our institutional review board prior
to identifying patients at our tertiary care referral center from May 1990 to August 2011 with
RCC and level III-IV IVC thrombi who underwent
a radical nephrectomy and IVC thrombectomy
on either VVB or CPB. Prior to their operation,
a complete metastatic evaluation was conducted
which included history, physical examination, and
serological studies that included serum creatinine,
complete blood count, calcium assessment, and liver function studies. Patients were also screened
with chest x-ray or non-contrast computed tomography (CT) or magnetic resonance imaging (MRI),
both with intravenous contrast when no contrain-
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Statistical analysis

was 40.0% versus 31.3% (P=1.0) in the VVB versus
the CPB group. Notably, two perioperative mortalities occurred in the CPB group (on postoperative
days 2 and 13). The death at postoperative 2 day
occurred from renal insufficiency and haemothorax formation. The death at postoperative day 13
occurred from sepsis caused by an enterococcus
infection. Additionally, the need for post-operative blood transfusions occurred in 0 of the VVB
group and 43.8% of the CPB group (P=0.12).
Overall, we did not discover any statistical difference in the perioperative characteristics
between VVB versus CPB when analyzing median
EBL (2300 mL versus 3250 mL, P=0.35), intraoperative pRBC’s transfused (6 units versus 8 units,
P=0.66), operative time (362 minutes versus 403
minutes, P=0.28), anesthesia time (407 minutes vs.
473 minutes, P=0.18), and length of hospital stay
(8 days versus 11 days, P=0.21). There was a trend
however, towards decreased total time on vascular
bypass in patients undergoing VVB (29 minutes
versus 60 minutes, P=0.09). These results are shown in Table-3.
The median post-operative follow-up for
the entire population was 11.93 months (IQR:
5.59-29.92 months). The median OS for the entire population was relatively low at 16.1 months
(IQR: 6.3-32.5 months) with a comparable median
estimated DSS for the entire population of 20.6
months (IQR: 6.3-84.8 months). Utilization of one
form of bypass over the other did not predict OS
or DSS. Median OS in the VVB group was 20.6
months versus 10.16 months (IQR: 5.6-84.8) in
the CPB group (P=0.80) with 2-year OS rates of
50% (VVB) and 40% (CPB). The overall DSS for
the VVB versus the CPB group was 20.6 months
(IQR: 6.3-29.9 months) versus 10.2 months (IQR
5.6-84.8 months, P=0.60) with 2-year DSS rates of
50% (VVB) and (50%).

Estimated blood loss, intra-operative
PRBC transfusions, post-operative PRBC transfusions, time on bypass, operative time, anesthesia
time, length of hospital stay, overall survival (OS),
disease specific survival (DSS) and complication
rates were compared between the CPB and VVB
groups. Comparisons between groups were made
using Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. The Kaplan-Meier method was used to estimate overall and disease-specific survival from
the time of surgery, with comparisons made using
the log-rank test. Two patients that died in the
peri-operative period were omitted from the survival analysis as they died prematurely on the study.
As such an intention to treat analysis was not performed. All p-values reported are two-tailed with
statistical significance set when p<0.05. Statistical
analyses were conducted using SPSS 21 (IBM Software division, Somers, NY, USA).
RESULTS
Our patient population consisted of 21 patients that had been treated by nephrectomy and
concomitant IVC thrombectomy for RCC utilizing
either CPB (n=16) or VVB (n=5). Of this group, 17
patients were classified as having level IV thrombi (81%) and 4 were classified as having level III
thrombi (19%). The median age of the population
was 64 years (43-84). Patients undergoing surgical
resection had an overall good performance status,
with 20 of 21(95.0%) patients having an Eastern
Cooperative Oncology Group Performance Status
(ECOG PS) of 0 or 1. The clinical and pathological characteristics of the two patient subsets (VVB
and CPB) are summarized in Table-1.
The type of bypass utilized was not predictive of overall, minor, or major complication rate.
These complication rates were determined using
the validated Dindo-Clavien classification system.
The overall complication rate was 60.0% in the
VVB group versus 62.5% in the CPB group (P=1.0,
Table-2). Additionally the minor complication rate
(Clavien I and II) was 60.0% versus 68.7% (P=1.0)
and the major complication rate (Clavien IIIa-V)

DISCUSSION
In our current study we attempted to determine if any benefit exists in utilizing VVB over
CPB in patients undergoing IVC tumor thrombectomy with concomitant radical nephrectomy
for RCC. We assessed our surgical experience in
conducting high level IVC tumor thrombi (level III
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Table 1 - Patient Clinical and Pathological Characteristics.
Feature

VVB (n=5)

CPB (n=16)

Level III

3(60.0)

1(6.25)

Level IV

2(40.0)

15(93.75)

45(43-83)

65(53-84)

3/2

8/8

N+

2(40.0)

5(31.25)

M+

0

5(31.25)

Clear Cell

4(80.0)

7(43.75)

Papillary

0

6(37.50)

Chromophobe

0

0

Not Specified

1(20.0)

3(18.75)

1

0

0

2

1(20.0)

2(12.50)

3

3(60.0)

4(25.00)

4

1(20.0)

5(31.25)

0

5(31.25)

0

3(60.0)

9(56.25)

1

2(40.0)

6(37.50)

2

0

1(6.25)

29.3 (20.9-35.9)

27.6 (19.5-42.3)

Tumor Thrombus Level

Age at Surgery
Median (Range)
Gender M/F
Extent of Disease at Time of Surgery

Histologic Subtype

Nuclear Grade

Not Otherwise Specified
ECOG

BMI
Median (Range)

CPB = Cardiopulmonary Bypass; VVB =Veno-Venous Bypass; BMI = Body Mass Index, RCC = Renal Cell Carcinoma; M = male; F = Female; ECOG = Eastern
Cooperative Oncology Group Status
(Data in parenthesis are percentages)

and IV) using either VVB or CPB techniques. We
have shown that both approaches can be successfully performed safely acknowledging a high peri-operative complication rate in such challenging
surgical procedures for locally advanced disease.
Traditionally the use of CPB was utilized in
almost all cases of level III and IV tumor thrombi. Due to the known complications of renal and
hepatic failure, neurologic dysfunction, postoperative sepsis, and systemic coagulopathy associa-

ted with CPB, alternative techniques have been
attempted to reduce these complications (1, 16,
21, 22). Some level III thrombi can be successfully
managed utilizing orthotopic liver transplant techniques that involves cross clamping of the IVC.
This technique was reported by Cianco et al., and
reduces the inherent risk associated with vascular
bypass. The decrease in cardiac return after IVC
cross clamping however is sometimes not tolerable in a select group of patients (Supp. Figure-1).
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Table 2 - Overall Complication Rate By Clavien Classification.
Complication By Clavien Classification

VVB(n=5)

CPB(n=16)

Atrial Fibrillation II

0

3(18.75)

Cephalic Vein Thrombus II

0

1(6.25)

Chylous Fistula II

0

1(6.25)

1(20.0)

0

Volume Overload II

0

1(6.25)

Pneumothorax IIIa

0

1(6.25)

Cardiac Tamponade IIIb

0

1(6.25)

Myocardial Infarction IV

1(20.0)

0

Pulmonary Embolus IV

1(20.0)

0

0

2(12.5)

Deep Vein Thrombosis II

Mortality V
Data in parenthesis are percentages. (P=1.0)

Table 3 - Perioperative characteristics.
Features

VVB(n=5)

CPB(n=16)

P Value

2300(1300-5200)

3250(900-9000)

0.35

6(4-12)

8(1-38)

0.66

34 (20-50)

64 (16-138)

0.09

Operative Time (min)

362 (288-478)

403 (248-865)

0.28

Anesthesia Time (min)

407 (300-541)

473 (384-955)

0.18

8 (5-10)

11 (2-20)

0.21

Estimated Blood Loss (mL)
Intra-operative pRBC’s (units)
Bypass Time (min)

Length of Hospital Stay (min)
pRBC-packed red blood cells
Data is reported as medians with range demonstrated in parentheses.

As such, the use of bypass is clearly beneficial
and encouraged (Supp. Figure-2). As excessive
post-operative bleeding can occur in up to 11%
of patients after undergoing CPB however, VVB
has been used to possibly reduce the risk of postoperative coagulopathy (24). Initially utilized
for liver transplantation, VVB has the advantage
that it does not require systemic anti-coagulation, as the cannulas are pre-coated with heparin
(16, 22, 23, 25).
The use of VVB in IVC thrombectomy has
been described extensively in the literature (10, 11,
16, 26-29). However, only one prior retrospective

study conducted by Granberg et al. has compared
VVB versus CPB bypass in the setting of RCC and
IVC tumor thrombi (16). This study demonstrated
patients undergoing VVB (n=13) had significantly shorter bypass, operative, and anesthesia times
than did patients treated with CPB (n=28). The
study also demonstrated trends towards decreased intraoperative blood loss, reduced transfusion
requirements, and a shorter length of hospitalization with VVB. In our current study, we sought
to perform an extensive analysis of complications
while comparing similar peri-operative characteristics to the previous study. In our study we did
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Supplementary Figure 1 - Vascular control during right radical nephrectomy with inferior vena cava (IVC) thrombectomy without
bypass utilizing the orthotopic liver transplant technique. Temporary clamps are placed on the hepatic hilum (hepatic artery,
portal vein, and common bile duct) via the Pringle maneuver, suprahepatic IVC, infrarenal IVC, and left renal vein. If no collateral
circulation exists between the suprahepatic IVC and the right atrium, decreased cardiac preload can lead to hypotension.

not discover trends towards decreased intraoperative blood loss, reduced transfusion requirements,
and shorter length of hospital stay with the use
of VVB. This could in part be from the limited
power of our study or perhaps a selection bias,
as any patient undergoing IVC thrombectomy for
RCC is subject to substantial blood loss, leading to
increased transfusion requirements, and possibly
an increased hospital stay. Our study also differed
from the previous, (16) as we only demonstrated a
trend in decreased time on bypass and showed no
statistical difference in operative time and anesthesia time. It could be assumed that since VVB
only requires percutaneous access and not direct
access to the vasculature like CPB, there would
be a decrease in operative and anesthesia time.
However since at our institution vascular bypass

is reserved for cases that require extensive mobilization and resection of the tumor thrombi, increased operative time, anesthesia time, and time on
bypass would be increased in all cases (27).
Prior studies demonstrated comparable survival rates of patients with level III and IV tumor
thrombi after surgical resection (5). As evidenced
by our current study as well the study conducted
by Granberg et al., utilizing VVB versus CPB provides no increase in OS or DSS with one form of
bypass versus another. This is conceivable as both
modalities allow for adequate resection of tumor
thrombi and both involve a substantial and comparable insult to the cardiovascular system. As such,
it is quite feasible that if the patient successfully
recovers from the perioperative period, there will be
no differences in intermediate long-term survival.

916

ibju | Effect of type of bypass on complications for high level inferior vena cava tumor thrombectomy

Supplementary Figure 2 - Vascular control during right radical nephrectomy with inferior vena cava (IVC) thrombectomy utilizing
veno-venous bypass (VVB). Similar to the orthotopic liver transplant technique, temporary clamps are placed on the hepatic hilum
(hepatic artery, portal vein, and common bile duct) via the Pringle maneuver, suprahepatic IVC, infrarenal IVC, and left renal vein.
Cardiac preload is restored by the bypass of the portal and venous circulation via cannulation (direction of flow depicted by arrows)
of the femoral vein returning blood flow to the right atrium.

We discovered no difference in minor,
major, or overall complication rate when comparing VVB versus CPB utilizing the Dindo-Clavien
Classification system. Significant major complication rates (Dindo-Clavien IIIa-V) were evident
in both the VVB (40.0%) and the CPB (31.3%)
group. Notably there were two post-operative deaths (Clavien V) as well as one pneumothorax
(Clavien IIIa) and one case of cardiac tamponade
(Clavien IIIb) in the CPB cohort. Similarly, one
intra-operative myocardial infarction (Clavien
IVa) and one post-operative pulmonary embolus
(Clavien IVa) occurred in the VVB group. Additionally no difference in minor complications
between VVB and CPB were observed. As there is no statistical difference in minor, major, or
overall complication rates between the VVB and

CPB groups, our study demonstrates that both
modalities are associated with significant complications in the perioperative period. Although
the use of VVB eliminates the use of systemic
anticoagulation, this is only one variable that
contributes to post-operative coagulopathy. Consumptive coagulopathy, which is caused by introducing red blood cells to foreign surfaces such
as connecter tubing used in both VVB and CPB,
increases the expression of tissue factor, which in
turn initiates the coagulation cascade leading to
consumption of coagulation factors and platelets
(23, 24). As substantial post-operative complications can occur when using either VVB or CPB to
successfully resect IVC tumor thrombi, knowledge of these complications is paramount for surgical planning and post-operative management.
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We acknowledge that our study is limited by its relatively small sample size as well as
our single-institution retrospective design. We
also acknowledge an inherent selection bias in
our study as we utilize a multidisciplinary decision making process and not specific criteria to
determine which patients undergo VVB versus
CPB. However, in light of this, our study does not
necessarily support the use of VVB over CPB in
the setting of IVC thrombectomy. As both methods
have similar survival and complication rates, the
select use of VVB could be employed on high level
thrombi (III/IV) on an individualized basis.
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